Stephanie Brown
Primary Care · Kenosha, WINPI 1891260543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,354, 2.2 times the $619 reported in 2021. Among primary care clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$588
- AbbVie$461
- Aimmune Therapeutics, Inc.$279
- Lilly USA, LLC$194
- Pfizer$162
- AstraZeneca$116
- plus $790 from 19 others
What the payments were for
- Food & beverage$2,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $588 |
| AbbVie | 22 | $461 |
| Aimmune Therapeutics, Inc. | 11 | $279 |
| Lilly USA, LLC | 12 | $194 |
| Pfizer | 9 | $162 |
| AstraZeneca | 7 | $116 |
| Exact Sciences | 5 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Boehringer Ingelheim | 6 | $87 |
| GSK | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Dexcom, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Abbott | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Sanofi | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$2,588 in reported general payments places this provider in the 95th percentile of 52 primary care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $53,942 |
| EliquisApixaban | 38 | $25,176 |
| OzempicSemaglutide | 20 | $19,041 |
| JardianceEmpagliflozin | 14 | $10,973 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,088 |
| Atorvastatin Calcium | 253 | $2,289 |
| Candesartan Cilexetil | 14 | $1,876 |
| Gabapentin | 60 | $1,389 |
| SynthroidLevothyroxine Sodium | 20 | $1,335 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,230 |
| Levothyroxine Sodium | 153 | $1,212 |
| Omeprazole | 81 | $1,119 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,059 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,043 |
| Bupropion XlBupropion Hcl | 34 | $999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $194 | $53,94239 claims |
| PfizerEliquis | $162 | $25,17638 claims |
| Novo NordiskOzempic | $588 | $19,04120 claims |
| Boehringer IngelheimJardiance | $87 | $10,97314 claims |
| AstraZenecaSymbicort | $116 | $4,08811 claims |
| AbbVieSynthroid | $461 | $1,33520 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $30 | $37417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 primary care providers in Wisconsin.
Other primary care in Kenosha
- Janet BarneyKenosha$527
- Michael PotnekMilwaukee$71K
- Jennifer KrallWausau$4K
- Emily OrganBrookfield$2K
- Heather MeeusenPlymouth$2K
- Kelly StoneMilwaukee$2K
- Courtney LammMilwaukee$2K
- Mary WiseMilwaukee$2K
- Dayna OsborneJanesville$1K
- Jennifer ErichPleasant Prairie$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.